Department of Adult Psychiatry, Medical University of Lodz, Lodz, Poland.
Neurosci Lett. 2012 Feb 29;510(2):127-31. doi: 10.1016/j.neulet.2012.01.018. Epub 2012 Jan 17.
BACKGROUND/AIM: Depressive disorders are multifactorial diseases, in which cognitive impairment is one of the characteristic feature. One of the molecules that regulate of various cognitive, emotional and behavioural processes is nitric oxide (NO), synthesized from l-arginine by a family of isoformic enzymes known as nitric oxide synthases (NOS). NO is a gaseous compounds that acts as a biological second messenger in a number of organ system. In addition, NO is a ubiquitous free radical (NO) that affects many normal physiologic functions but is also implicated in the etiology and progression of many diseases. The aim of the study was to determine the concentration of NO in patients with recurrent depressive disorder (rDD) and to define relationship between plasma NO levels and the cognitive performance.
The study comprised 78 subjects: patients with rDD (n=45), healthy controls (CG, n=33). Cognitive function assessment was based on: TMT, The Stroop Test, VFT, AVLT.
Statistically significant differences were found among patients with rDD in the intensity of depression symptoms, measured by the HDRS on therapy onset vs. the examination results after 8 weeks of treatment (p<0.001). The level of NO was substantially higher in patients with rDD compared to CG. For all examined subjects (p<0.001), elevated levels of NO in blood plasma adversely affect the efficiency of visual-spatial and auditory-verbal working memory as well as short-term declarative memory. For rDD patients, elevated NO levels were associated with worse cognitive test performance. The higher was the concentration of plasma NO, the greater was the severity of depressive symptoms measured by HDRS (p=0.03).
(1) Higher concentration of plasma NO in rDD patients is associated with the severity of depressive symptoms. (2) Elevated levels of plasma NO are related to impairment of visual-spatial and auditory-verbal working memory as well as to impairment of short-term declarative memory.
背景/目的:抑郁障碍是一种多因素疾病,认知障碍是其特征之一。调节各种认知、情绪和行为过程的分子之一是一氧化氮(NO),它由一系列同工型酶(即一氧化氮合酶[NOS])从 l-精氨酸合成。NO 是一种气体化合物,作为许多器官系统中生物第二信使发挥作用。此外,NO 是一种普遍存在的自由基(NO),它影响许多正常的生理功能,但也与许多疾病的病因和进展有关。本研究的目的是确定复发性抑郁障碍(rDD)患者中 NO 的浓度,并定义血浆 NO 水平与认知表现之间的关系。
该研究包括 78 名受试者:rDD 患者(n=45)和健康对照组(CG,n=33)。认知功能评估基于:TMT、Stroop 测试、VFT、AVLT。
在 rDD 患者中,治疗开始时 HDRS 测量的抑郁症状严重程度与治疗 8 周后的检查结果之间存在显著差异(p<0.001)。与 CG 相比,rDD 患者的 NO 水平显著升高。对于所有检查对象(p<0.001),血浆中升高的 NO 水平会降低视觉空间和听觉言语工作记忆以及短期陈述性记忆的效率。对于 rDD 患者,升高的 NO 水平与认知测试表现较差有关。血浆 NO 浓度越高,HDRS 测量的抑郁症状严重程度越大(p=0.03)。
(1)rDD 患者血浆中较高浓度的 NO 与抑郁症状的严重程度有关。(2)血浆中升高的 NO 水平与视觉空间和听觉言语工作记忆受损以及短期陈述性记忆受损有关。